Reading the offer · 6 company examples
FDA Letters About Names on Compounded Vial Labels
Who made the medication behind the price?
These letters focus on a pictured vial label identifying a seller as though it compounded the medication. The distinction matters when the company taking payment and the pharmacy preparing a prescription are different businesses.
A familiar logo is not a substitute for identifying the pharmacy. Before comparing two quotes as equivalent, establish which entity prepares and dispenses the drug and what the quoted service includes. These letters do not establish that a batch was contaminated or that a particular price was false.
The examples here are label-focused. The separate guide on labels and drug claims covers letters that also challenge the advertising around the pictured product.
An FDA warning letter is a public regulatory communication stating the agency's view. It is not a recall, a fine, a criminal charge, an injunction, or a finding that a company has broken the law.
This guide was organized in October 2026. Each company’s source-check date below is kept separately; the guide date does not mean its letter status was checked again.
Letter issued · Status last checked · Active at that check
What FDA cited
FDA said the compounded semaglutide and tirzepatide products displayed on Ezra's website identify "Ezra" on the pictured label, "suggesting Ezra is the compounder of those drugs when in fact it is not" — the same labeling-attribution finding cited against MEDVi and Strut in this dataset, applied here to Ezra, a brand best known for full-body MRI scans rather than compounding.
What it means for the offer
Ezra expanded from full-body MRI scans into compounded GLP-1s, and this letter is about how that new product line was labeled, not about the scans it's known for or a finding that the medication is unsafe. A pictured label carrying the retailer's own brand name, when a separate pharmacy actually compounds the drug, is the specific thing FDA objected to — it's worth checking whose name is actually on the label before assuming the seller made the medication.
Quoted passages and recorded context
Violations were identified and documented during a review of Ezra's website […], FDA Establishment Identifier (FEI) 3045074898, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.
1. The compounded semaglutide and tirzepatide products displayed on your website identify "Ezra" on the pictured label, suggesting Ezra is the compounder of those drugs when in fact it is not.
Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act.
Ezra's website and its second website were both live storefronts when we checked in August 2026 (the address typed without "www" shows an error page, which is a setup quirk, not evidence the business has closed).
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Mint Med
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA listed exactly one violation and quoted no marketing copy whatsoever: the compounded semaglutide and tirzepatide products displayed on the website "identify “Mint Med” on the pictured label, suggesting Mint Med is the compounder of those drugs when in fact it is not." The finding is about the picture of the vial, not about anything written beside it, and FDA concluded that those representations "cause your compounded drug products to be misbranded". The letter asks the company to identify "the entities that produce the compounded drug products offered on your website" — the question the label had answered wrongly.
What it means for the offer
Almost every letter in this collection quotes something the seller wrote. This one quotes nothing, because there was nothing to quote — FDA's entire finding is that the vial in the product photograph had the storefront's name on it, and the storefront did not make the drug. That is worth sitting with, because it is the finding a shopper is least equipped to catch. Marketing copy can be read and doubted; a label in a product image reads as documentation. Under FDA's regulation, a name printed on a drug label without qualification is a representation that the named party is the sole manufacturer, so putting a brand on the vial answers the question "who made this" — and here it answered it incorrectly. The practical consequence is about traceability rather than danger: if the compounder's name is not on the label, then a buyer cannot look up the facility, cannot check whether it is a 503A pharmacy or a registered 503B outsourcing facility, and has no way to connect a bad batch to a source. FDA asked the company to name the producing entities, which is the same question a careful buyer would ask. Nothing in the letter concerns the drug's quality or contents. The site is trading today at $159 a month for all doses, a price shape that only makes sense when someone else is doing the compounding.
Quoted passages and recorded context
Violations were identified and documented during a review of Mint Med’s website, [Mint Med's website], FDA Establishment Identifier (FEI) 3044896930, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products. As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.
1. The compounded semaglutide and tirzepatide products displayed on your website identify “Mint Med” on the pictured label, suggesting Mint Med is the compounder of those drugs when in fact it is not.
1. Identifying the entities that produce the compounded drug products offered on your website;
Mint Med's website was a live storefront in August 2026, titled "MintMed | Doctor-Backed Treatments for Wellness & Vitality", advertising "GLP-1 All Doses $159 per month" and "NO memberships!", publishing a Cincinnati phone number (1-513-826-6142) consistent with the Ohio address on the letter, and running a $25 referral offer with a working checkout — an operating seller. No brand names (Ozempic, Wegovy, Mounjaro, Zepbound) appeared on the homepage when we looked.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Nexlife
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA made one finding and it is entirely about the vial. The compounded semaglutide and tirzepatide products shown on the site "identify “Nexlife” on the pictured label, suggesting Nexlife is the compounder of those drugs when in fact it is not." No advertising copy is quoted anywhere in the letter, and no claim is made about the pharmacy behind the product — the numbered list opens at "1." and ends there. FDA's footnote gives the rule the finding rests on: under 21 C.F.R. § 201.1(h)(2), "The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product."
What it means for the offer
Strip a letter down to one sentence and you can see exactly what it does and does not touch. Nothing here is about the medicine, the dose, the price or the clinic. It is about a name printed on a vial, and FDA's position — set out in the regulation it cites — is that putting your name on a drug label unqualified means you made it. Nexlife did not. For a reader comparing monthly prices, that matters in a narrow, practical way: the company setting the price and the company compounding the drug are two different businesses, and the label as pictured did not let you tell them apart. It says nothing about whether $155 a month is a good deal or a bad one. It says the branding on the box was not evidence of who was behind it, so any confidence you drew from seeing a name on the product has to be rebuilt from somewhere else.
Quoted passages and recorded context
Violations were identified and documented during a review of Nexlife’s website, [Nexlife's website], FDA Establishment Identifier (FEI) 3044820290, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.
1. The compounded semaglutide and tirzepatide products displayed on your website identify “Nexlife” on the pictured label, suggesting Nexlife is the compounder of those drugs when in fact it is not.
See 21 C.F.R. § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”)
In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&C Act
Nexlife's website returned a live storefront on 2026-08-09 titled "Nexlife", advertising "Semaglutide Weight Loss Online Prices start from $165 per month*" and GLP-1 treatment "As low as $155 /mo*" on a 12-month plan, with add-to-cart markup present in the page.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
VIV RX
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA made one finding and quoted no marketing copy in support of it. The products pictured on the site "identify “VIV RX” on the pictured label, suggesting VIV RX is the compounder of those drugs when in fact it is not," and FDA concluded that "the representations on your website that VIV RX is the compounder of these drug products are false or misleading." Nothing the company wrote about what the medication does, how well it works or what it costs appears anywhere in the letter — the entire violation is the name on the vial.
What it means for the offer
This is the smallest letter in the set, and that is exactly what makes it worth reading. There is no disputed efficacy claim here, no price comparison, no argument about whether a sentence oversells a result — the company's own marketing language is not quoted once. What FDA objected to is that the vial in the product photo carried the brand's name, which under FDA's reading tells you the brand made the drug. It did not; a compounding pharmacy did, and the letter says the pharmacy was never named. For a shopper, the practical question that raises is not whether the medicine works. It is who you would be dealing with if something went wrong — who mixed it, under whose license, and whether the company whose name is on the box could answer that. A letter this narrow says nothing at all about the product's safety. It does say that the most basic fact on the label, the maker, was not the one printed there.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [VIV RX's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products. As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
The compounded semaglutide and tirzepatide products displayed on your website identify “VIV RX” on the pictured label, suggesting VIV RX is the compounder of those drugs when in fact it is not. Accordingly, the representations on your website that VIV RX is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
VIV RX's website returned a live site on 2026-08-09 titled "Personalized, Science-Backed Weight Loss | Viv", with compound semaglutide and compound tirzepatide listed in the shop navigation alongside a get-started flow — an operating storefront rather than a closed one.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
VivioMD
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA quoted no marketing copy and listed one violation: the compounded semaglutide and tirzepatide products displayed on the website "identify “VivioMD” on the pictured label, suggesting VivioMD is the compounder of those drugs when in fact it is not." The finding is about the vial in the product photograph, not about a sentence anyone wrote, and FDA concluded those representations "cause your compounded drug products to be misbranded". The first thing FDA asked for in response was a list — "Identifying the entities that produce the compounded drug products offered on your website".
What it means for the offer
Three letters in this collection say the same single thing — the name on the pictured vial was the storefront's own, and the storefront did not make the drug. What separates this one is that you can now go and read the answer. The page names its fillers outright: "your order may be filled by one of our pharmacy partners: RedRock Pharmacy, Health Warehouse, Precision Medicine, or Triad Rx." It says "VivioMD is not a pharmacy or a manufacturer of any medication." And it tells you the photographs are staged: package images "are for illustration only; actual packaging may vary depending on the compounding pharmacy that prepares your medication." That last line is the whole letter in one sentence, written by the seller. For a buyer the useful move is the one that disclosure makes possible: with a pharmacy's name you can look it up — check the state board, check whether it is a 503A pharmacy or a registered 503B outsourcing facility, check whether it has its own inspection history. Without a name you are trusting a photograph. Nothing here concerns what was in the vials; FDA made no finding about the drug's quality or contents, and has not closed the letter out.
Quoted passages and recorded context
Violations were identified and documented during a review of VivioMD’s website, [VivioMD's website], FDA Establishment Identifier (FEI) 3044027316, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.
1. The compounded semaglutide and tirzepatide products displayed on your website identify “VivioMD” on the pictured label, suggesting VivioMD is the compounder of those drugs when in fact it is not.
Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a) and (bb)].
1. Identifying the entities that produce the compounded drug products offered on your website;
2. Providing a representative sample of labeling for such drug products; and
VivioMD's website returned a live, fully served storefront on 2026-08-09 — titled "Vivio · Personalized care (Aura system)", trading under the shortened wordmark "vivio", with Women/Men weight-care and longevity paths, an intake assessment and a working sign-in. That is a check of whether the site is up and what it says; it is not a check of anything the letter alleges.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
WeightCare
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA made a single finding, and it is about the vial rather than the copy. The compounded semaglutide and tirzepatide products shown on the site "identify “WeightCare” on the pictured label, suggesting WeightCare is the compounder of those drugs when in fact it is not," so "the representations on your website that WeightCare is the compounder of these drug products are false or misleading, and the products are therefore misbranded". No advertising claim is quoted anywhere in the letter — and its closing paragraph reflects that, referring only to "The representations identified in this letter" where letters citing marketing copy in the same wave say "representations and claims".
What it means for the offer
There is an asymmetry on this page that a price shopper should see plainly. The pricing is specific and public — $499 a month, $997 for twelve weeks at 7.5 mg, $1350 at the high dose — and the company behind it was, at the time FDA wrote, hard to place: the agency's own recipient block records no street address at all, only a country and an email on the same domain as the shop. Then the one finding FDA made is that the name printed on the vial is not the name of whoever compounded it. Put those together and the picture is a business that is transparent about what it charges and opaque about who it is and who makes the product. That is not a safety finding, and nothing here suggests the medication is other than what a compounder supplied. It is a finding about traceability, and traceability is exactly what you would want before committing to a three-month prepayment, because a renewal schedule is a bet on a company still being there to honor it.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [WeightCare's website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.
The compounded semaglutide and tirzepatide products displayed on your website identify “WeightCare” on the pictured label, suggesting WeightCare is the compounder of those drugs when in fact it is not.
Accordingly, the representations on your website that WeightCare is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA
The representations identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.
WeightCare's website returned a live storefront on 2026-08-09 titled "Semaglutide and Tirzepatide Online | WeightCare", publishing renewal pricing directly on the page — a $499 monthly renewal, a $997 three-month renewal for 7.5 mg/week over 12 weeks, and a $1350 three-month high-dose renewal for up to 15 mg/week — with add-to-cart markup present.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.